



BABASAHEB BHIMRAO AMBEDKAR UNIVERSITY, LUCKNOW
(A Central University)

(Form to be filled by the Principal Investigator (PI) for submission to Institutional Ethics Committee (IEC)

(for attachment to each copy of the proposal)

***IEC Code No.** (To be filled by the Bioethics cell):

Study/Protocol No. (For drug/device trials/any other, to be filled by PI):

Type of project: Intramural [] Extramural [] Drug trial/device [] Independent []

MD/DM/PhD/SRF/M.Sc Project [] Collaborative [] Other []

Status of review: New [] Revised []

Proposal Title:.....

.....

	Name, Designation & Qualifications	Address, Tel & Fax Nos. Email ID	Signature
PI			
Co-PI / Collaborators			
1.			

Please attach detailed Curriculum Vitae of all Investigators (with subject specific publications limited to previous 5 years) not working at B.B.A.U. The investigators should sign their CV.

Sponsor Information

1. Indian	a. Government [] Central [] State [] Institutional []
	b. Private []
2. International	Government [] Private [] UN Agencies []
3. Industry	National [] Multinational []
4. Contact Address of Sponsor:	
Total Budget	

1. Study Type :			
2. Status of Review	New []	Revised []	
3. Clinical Trials:			
Drug/Vaccines/Device/Herbal Remedies:			
i. study involves use of	Drugs []	Device []	Vaccines []
	Indian system of medicine/ alternate system of medicine []		NA []
II. is it approved and marketed	Yes []	No []	
iii. Does it involve a change in use, dosage, route of administration?	Yes []	No []	
If Yes , weather DCGI's/ any other Regulatory Authority's permission obtained?	Yes []	No []	
If Yes , date of permission attached.			
iv. Is it an investigational New drug?	Yes []	No []	
If Yes,			
a) Investigator's Brochure enclosed	Yes []	No []	
b) Preclinical studies data available (if yes provide summary)	Yes []	No []	
c) Clinical studies data available (if yes provide summary)	Yes []	No []	
d) Clinical Study is	Phase I []	Phase II []	Phase III []
			Phase IV []
e) DCGI's permission obtained (if yes, copy of letter enclosed)	Yes []	No []	
4. Brief summary of proposal (Annexure-II) attached	Yes []	No []	

5. Subject Selection :				
i. Number of Subjects:				
ii. Duration of	a) Study:	b) Subject participation:		
iii. Type of Subjects:	Volunteers []	Patients []		
iv. Inclusion and Exclusion Criteria given	Yes []	No []		
v. Sex of the subjects for study	Male []	Female []	Both []	Transgender []
vi. Vulnerable Subjects	Yes []	No []		
If Yes, Tick Apt				
Pregnant women []	Children []	Elderly []	Foetus []	
Terminally III []	Illiterate []	Mentally challenged []		
Economically & socially Backward []	Any Other []			
vii. Special group subjects	Yes []	No []		
If yes, specify				
6. Privacy and Confidentiality				
i. Study involves:	Direct Identifiers []	Indirect Identifiers/ Coded []		
	Completely anonymous/delinked []			
ii. Confidential handling of data by staff	Yes []	No []		

7. Details of Sample Collection

A. Regarding sample collection

1. Collection of organs or body fluids or blood. If yes, please specify Yes No

Type: _____

Amount each time _____ ml Total _____ ml

No. of time in 2 week _____ Total (in 2 weeks) _____ ml

2. Collection of fetal tissue or abortus. If yes, please specify Yes No

3. Use of pre-existing/stored/left over samples. If yes, please specify Yes No

4. Proper disposal of material Yes No

B. Special situation

1. Will any sample collected from the patients be sent abroad? Yes No

If yes, give details and address of collaborators

a. Sample will be sent abroad because (Tick appropriate box)

Facility not available in India

Facility in India inaccessible

Facility available but not being accessed

If so, reasons _____

b. Has necessary clearance been obtained Yes No

2. Collection for banking/future research Yes No

8. Use of Biological/ hazardous materials

i. Use of fetal tissue or abortions (if yes provide detail)	Yes []	No []
ii. Use of body organs/ fluids (if yes, provide detail)	Yes []	No []
iii. Use of recombinant gene therapy	Yes []	No []
If yes, has Department of Biotechnology (DBT) approval for rDNA products been obtained?		
iv. Use of pre-existing stored / left over samples	Yes []	No []
v. Collection for banking future research	Yes []	No []
vi. Use of ionising radiation/ radioisotopes	Yes []	No []
If Yes, has Bhabha Atomic Research centre (BARC) approval for radioactive isotopes have been obtained? Yes/No		
vii. Use of Infectious/ biohazardous specimens	Yes []	No []
viii. Proper disposal of material	Yes []	No []

9. Participant Information Document (PID) and Consent form:

1. Consent *Written Oral Audio-Visual

Patient Information documents and consent form attached : (Tick the included elements)

Understandable language Alternatives to participation

Statement that study involves research Confidentiality of records

Sponsor of study Contact information

Purpose and procedures Statement that consent is voluntary

Risks & discomforts Right to withdraw

Benefits Benefits if any on future

Consent for future use of material biological

Free supply of drug till it is not marketed in country if necessary

Compensation for study related injury

Translation of Participant Information Document (PID) in local Language

2. **If healthy volunteers, PID for them** Yes No

3. **If participant is child, PID for parent** Yes No

4. **PID and Assent Form for child 8-18 yrs** Yes No

5. **Consent form** in English Local Languages
(For participant/healthy volunteer/parent/legal guardian)

6. **Who will obtain consent?** PI-Co-PI Nurse/Counselor
Research Staff Any Other

**If written consent is not obtained, give reasons.....*

10. **Will any advertising be done for recruitment of Subjects?** Yes No
(Posters, flyers, brochure, websites – if so attach a copy)

11. **For archival of record by Bioethics cell for more** Yes No Not applicable
than 5 years required
If yes, for how many years.....

J. **Do you have conflict of interest?** Yes No
(Financial/Nonfinancial)
If yes, specify _____

Place:

Date:

Signature & designation of PI/ Co-PI/Collaborators